A Phase III Study of Docetaxel plus S-1 versus S-1 Alone in the Treatment of Curatively Resected Stage III Gastric Cancer

Trial Profile

A Phase III Study of Docetaxel plus S-1 versus S-1 Alone in the Treatment of Curatively Resected Stage III Gastric Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Nov 2016

At a glance

  • Drugs Docetaxel; Gimeracil/oteracil/tegafur
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Acronyms START 2
  • Most Recent Events

    • 15 Nov 2016 Planned End Date changed from 31 Mar 2021 to 31 Dec 2022.
    • 06 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top